


Mirdametinib ReNeu

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Mirdametinib ReNeu

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Non-cancerous soft-tissue tumour
Therapeutic Indication: Mirdametinib for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Experimental Arm: Mirdametinib
Control Arm: Single arm



